Mansur Zhussupbekov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mansur Zhussupbekov has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- James F. Antaki
Meinig School of Biomedical Engineering Cornell University Ithaca New York USA
10 shared publications - Rodrigo Méndez Rojano
IMAG, Univ Montpellier, CNRS, Montpellier, France
7 shared publications Greg W. Burgreen
Center for Advanced Vehicular Systems Mississippi State University Starkville Mississippi USA
3 shared publicationsJames F. Antaki
Affiliation Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America
3 shared publicationsAngela Lai
Affiliation Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America
2 shared publications- Harvey S. Borovetz
Department of Bioengineering, University of Pittsburgh
2 shared publications
Latest Publications
- 14 August 2025
- Published by Wiley in Artificial Organs
- Vol. 50 (2) , 209-220
Multi‐Objective CFD Optimization of an Intermediate Diffuser Stage for PediaFlow Pediatric Ventricular Assist Device
Background: Computational fluid dynamics (CFD) has become an essential design tool for ventricular assist devices (VADs), where the goal of maximizing performance often conflicts with biocompatibility. This tradeoff becomes even more pronounced in pediatric applications due to the stringent size constraints imposed by the smaller patient population. This study presents an automated CFD‐driven shape optimization of a new intermediate diffuser stage for the PediaFlow pediatric VAD, positioned immediately downstream of the impeller to improve pressure recovery. Methods: We adopted a multi‐objective optimization approach to maximize pressure recovery while minimizing hemolysis. The proposed diffuser stage was isolated from the rest of the flow domain, enabling efficient evaluation of over 450 design variants using Sobol sequence, which yielded a Pareto front of nondominated solutions. The selected best candidate was further refined using a local T‐search algorithm. We then incorporated the optimized front diffuser into the full pump for CFD verification and in vitro validation. Results: We identified critical dependencies where longer blades increased pressure recovery but also hemolysis, while the wrap angle showed a strong parabolic relationship with pressure recovery but a monotonic relationship with hemolysis. Counterintuitively, configurations with fewer blades (2, 3) consistently outperformed those with more blades (4, 5) in both metrics. The optimized two‐blade design enabled operation at lower pump speeds (14 000 vs. 16 000 RPM), improving hydraulic efficiency from 26.3% to 32.5% and reducing hemolysis by 31%. Conclusion: This approach demonstrates that multi‐objective CFD optimization can systematically explore complex design spaces while balancing competing priorities of performance and hemocompatibility for pediatric VADs.
- 14 August 2025
- Published by Wiley in Artificial Organs
- Vol. 50 (2) , 209-220
Multi‐Objective CFD Optimization of an Intermediate Diffuser Stage for PediaFlow Pediatric Ventricular Assist Device
Background: Computational fluid dynamics (CFD) has become an essential design tool for ventricular assist devices (VADs), where the goal of maximizing performance often conflicts with biocompatibility. This tradeoff becomes even more pronounced in pediatric applications due to the stringent size constraints imposed by the smaller patient population. This study presents an automated CFD‐driven shape optimization of a new intermediate diffuser stage for the PediaFlow pediatric VAD, positioned immediately downstream of the impeller to improve pressure recovery. Methods: We adopted a multi‐objective optimization approach to maximize pressure recovery while minimizing hemolysis. The proposed diffuser stage was isolated from the rest of the flow domain, enabling efficient evaluation of over 450 design variants using Sobol sequence, which yielded a Pareto front of nondominated solutions. The selected best candidate was further refined using a local T‐search algorithm. We then incorporated the optimized front diffuser into the full pump for CFD verification and in vitro validation. Results: We identified critical dependencies where longer blades increased pressure recovery but also hemolysis, while the wrap angle showed a strong parabolic relationship with pressure recovery but a monotonic relationship with hemolysis. Counterintuitively, configurations with fewer blades (2, 3) consistently outperformed those with more blades (4, 5) in both metrics. The optimized two‐blade design enabled operation at lower pump speeds (14 000 vs. 16 000 RPM), improving hydraulic efficiency from 26.3% to 32.5% and reducing hemolysis by 31%. Conclusion: This approach demonstrates that multi‐objective CFD optimization can systematically explore complex design spaces while balancing competing priorities of performance and hemocompatibility for pediatric VADs.
- 21 March 2025
- Published by MyJove Corporation
- No. 217,p. e67731
JoVE Video Dataset
The risk of thrombosis remains a significant concern in the development and clinical use of ventricular assist devices (VADs). Traditional assessments of VAD thrombogenicity, primarily through animal studies, are costly and time-consuming, raise ethical concerns, and ultimately may not accurately reflect human outcomes. To address these limitations, we developed an aggressive in vitro testing protocol designed to provoke thrombosis and identify potential high-risk areas within the blood flow path. This protocol, motivated by the work of Maruyama et al., employs a modified anticoagulation strategy and utilizes readily available components, making it accessible to most laboratories conducting in vitro blood testing of VADs. We demonstrated the utility of this method through iterative testing and refinement of a miniature magnetically levitated pediatric VAD (PediaFlow PF5). The method has been effective in identifying thrombogenic hotspots caused by design and manufacturing flaws in early VAD prototypes, enabling targeted improvements before advancing to animal studies. Despite its limitations, including the absence of pulsatile flow and the influence of donor blood characteristics, this protocol serves as a practical tool for early-stage VAD development and risk mitigation.
- 21 March 2025
- Published by MyJove Corporation
- No. 217,p. e67731
JoVE Video Dataset
The risk of thrombosis remains a significant concern in the development and clinical use of ventricular assist devices (VADs). Traditional assessments of VAD thrombogenicity, primarily through animal studies, are costly and time-consuming, raise ethical concerns, and ultimately may not accurately reflect human outcomes. To address these limitations, we developed an aggressive in vitro testing protocol designed to provoke thrombosis and identify potential high-risk areas within the blood flow path. This protocol, motivated by the work of Maruyama et al., employs a modified anticoagulation strategy and utilizes readily available components, making it accessible to most laboratories conducting in vitro blood testing of VADs. We demonstrated the utility of this method through iterative testing and refinement of a miniature magnetically levitated pediatric VAD (PediaFlow PF5). The method has been effective in identifying thrombogenic hotspots caused by design and manufacturing flaws in early VAD prototypes, enabling targeted improvements before advancing to animal studies. Despite its limitations, including the absence of pulsatile flow and the influence of donor blood characteristics, this protocol serves as a practical tool for early-stage VAD development and risk mitigation.
- 21 March 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 217,p. e67731
In Vitro Thrombosis Test for Ventricular Assist Devices
The risk of thrombosis remains a significant concern in the development and clinical use of ventricular assist devices (VADs). Traditional assessments of VAD thrombogenicity, primarily through animal studies, are costly and time-consuming, raise ethical concerns, and ultimately may not accurately reflect human outcomes. To address these limitations, we developed an aggressive in vitro testing protocol designed to provoke thrombosis and identify potential high-risk areas within the blood flow path. This protocol, motivated by the work of Maruyama et al., employs a modified anticoagulation strategy and utilizes readily available components, making it accessible to most laboratories conducting in vitro blood testing of VADs. We demonstrated the utility of this method through iterative testing and refinement of a miniature magnetically levitated pediatric VAD (PediaFlow PF5). The method has been effective in identifying thrombogenic hotspots caused by design and manufacturing flaws in early VAD prototypes, enabling targeted improvements before advancing to animal studies. Despite its limitations, including the absence of pulsatile flow and the influence of donor blood characteristics, this protocol serves as a practical tool for early-stage VAD development and risk mitigation.
- 21 March 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 217,p. e67731
In Vitro Thrombosis Test for Ventricular Assist Devices
The risk of thrombosis remains a significant concern in the development and clinical use of ventricular assist devices (VADs). Traditional assessments of VAD thrombogenicity, primarily through animal studies, are costly and time-consuming, raise ethical concerns, and ultimately may not accurately reflect human outcomes. To address these limitations, we developed an aggressive in vitro testing protocol designed to provoke thrombosis and identify potential high-risk areas within the blood flow path. This protocol, motivated by the work of Maruyama et al., employs a modified anticoagulation strategy and utilizes readily available components, making it accessible to most laboratories conducting in vitro blood testing of VADs. We demonstrated the utility of this method through iterative testing and refinement of a miniature magnetically levitated pediatric VAD (PediaFlow PF5). The method has been effective in identifying thrombogenic hotspots caused by design and manufacturing flaws in early VAD prototypes, enabling targeted improvements before advancing to animal studies. Despite its limitations, including the absence of pulsatile flow and the influence of donor blood characteristics, this protocol serves as a practical tool for early-stage VAD development and risk mitigation.
- Open Access
Exploratory Simulation of Thrombosis in a Temporary LVAD Catheter Pump within a Virtual In-vivo Left Heart Environment
Percutaneous catheter pumps are intraventricular temporary mechanical circulatory support (MCS) devices that are positioned across the aortic valve into the left ventricle (LV) and provide continuous antegrade blood flow from the LV into the ascending aorta (AA). MCS devices are most often computationally evaluated as isolated devices subject to idealized steady-state blood flow conditions. In clinical practice, MCS devices operate connected to or within diseased pulsatile native hearts and are often complicated by hemocompatibility related adverse events such as stroke, bleeding, and thrombosis. Whereas aspects of the human circulation are increasingly being simulated via computational methods, the precise interplay of pulsatile LV hemodynamics with MCS pump hemocompatibility remains mostly unknown and not well characterized. Technologies are rapidly converging such that next-generation MCS devices will soon be evaluated in virtual physiological environments that increasingly mimic clinical settings. The purpose of this brief communication is to report results and lessons learned from an exploratory CFD simulation of hemodynamics and thrombosis for a catheter pump situated within a virtual in-vivo left heart environment.
Open AccessExploratory Simulation of Thrombosis in a Temporary LVAD Catheter Pump within a Virtual In-vivo Left Heart Environment
Percutaneous catheter pumps are intraventricular temporary mechanical circulatory support (MCS) devices that are positioned across the aortic valve into the left ventricle (LV) and provide continuous antegrade blood flow from the LV into the ascending aorta (AA). MCS devices are most often computationally evaluated as isolated devices subject to idealized steady-state blood flow conditions. In clinical practice, MCS devices operate connected to or within diseased pulsatile native hearts and are often complicated by hemocompatibility related adverse events such as stroke, bleeding, and thrombosis. Whereas aspects of the human circulation are increasingly being simulated via computational methods, the precise interplay of pulsatile LV hemodynamics with MCS pump hemocompatibility remains mostly unknown and not well characterized. Technologies are rapidly converging such that next-generation MCS devices will soon be evaluated in virtual physiological environments that increasingly mimic clinical settings. The purpose of this brief communication is to report results and lessons learned from an exploratory CFD simulation of hemodynamics and thrombosis for a catheter pump situated within a virtual in-vivo left heart environment.
- Open Access
- 19 October 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (20) , 10554
Real-Time Prediction of Transarterial Drug Delivery Based on a Deep Convolutional Neural Network
This study develops a data-driven reduced-order model based on a deep convolutional neural network (CNN) for real-time and accurate prediction of the drug trajectory and concentration field in transarterial chemoembolization therapy to assist in directing the drug to the tumor site. The convolutional and deconvoluational layers are used as the encoder and the decoder, respectively. The input of the network model is designed to contain the information of drug injection location and the blood vessel geometry and the output consists of the drug trajectory and the concentration field. We studied drug delivery in two-dimensional straight, bifurcated blood vessels and the human hepatic artery system and showed that the proposed model can quickly and accurately predict the spatial–temporal drug concentration field. For the human hepatic artery system, the most complex case, the average prediction accuracy was 99.9% compared with the CFD prediction. Further, the prediction time for each concentration field was less than 0.07 s, which is four orders faster than the corresponding CFD simulation. The high performance, accuracy and speed of the CNN model shows the potential for effectively assisting physicians in directing chemoembolization drugs to tumor-bearing segments, thus improving its efficacy in real-time.
- 19 October 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (20) , 10554
Open AccessReal-Time Prediction of Transarterial Drug Delivery Based on a Deep Convolutional Neural Network
This study develops a data-driven reduced-order model based on a deep convolutional neural network (CNN) for real-time and accurate prediction of the drug trajectory and concentration field in transarterial chemoembolization therapy to assist in directing the drug to the tumor site. The convolutional and deconvoluational layers are used as the encoder and the decoder, respectively. The input of the network model is designed to contain the information of drug injection location and the blood vessel geometry and the output consists of the drug trajectory and the concentration field. We studied drug delivery in two-dimensional straight, bifurcated blood vessels and the human hepatic artery system and showed that the proposed model can quickly and accurately predict the spatial–temporal drug concentration field. For the human hepatic artery system, the most complex case, the average prediction accuracy was 99.9% compared with the CFD prediction. Further, the prediction time for each concentration field was less than 0.07 s, which is four orders faster than the corresponding CFD simulation. The high performance, accuracy and speed of the CNN model shows the potential for effectively assisting physicians in directing chemoembolization drugs to tumor-bearing segments, thus improving its efficacy in real-time.
- 3 October 2022
- Published by Elsevier in Biophysical Journal
- Vol. 121 (21) , 4033-4047
von Willebrand factor unfolding mediates platelet deposition in a model of high-shear thrombosis
- 3 October 2022
- Published by Elsevier in Biophysical Journal
- Vol. 121 (21) , 4033-4047
von Willebrand factor unfolding mediates platelet deposition in a model of high-shear thrombosis
- Open Access
- 3 October 2022
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 18 (10) , e1010277
A fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas
Over the past decade, much of the development of computational models of device-related thrombosis has focused on platelet activity. While those models have been successful in predicting thrombus formation in medical devices operating at high shear rates (> 5000 s−1), they cannot be directly applied to low-shear devices, such as blood oxygenators and catheters, where emerging information suggest that fibrin formation is the predominant mechanism of clotting and platelet activity plays a secondary role. In the current work, we augment an existing platelet-based model of thrombosis with a partial model of the coagulation cascade that includes contact activation of factor XII and fibrin production. To calibrate the model, we simulate a backward-facing-step flow channel that has been extensively characterized in-vitro. Next, we perform blood perfusion experiments through a microfluidic chamber mimicking a hollow fiber membrane oxygenator and validate the model against these observations. The simulation results closely match the time evolution of the thrombus height and length in the backward-facing-step experiment. Application of the model to the microfluidic hollow fiber bundle chamber capture both gross features such as the increasing clotting trend towards the outlet of the chamber, as well as finer local features such as the structure of fibrin around individual hollow fibers. Our results are in line with recent findings that suggest fibrin production, through contact activation of factor XII, drives the thrombus formation in medical devices operating at low shear rates with large surface area to volume ratios.
- 3 October 2022
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 18 (10) , e1010277
Open AccessA fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas
Over the past decade, much of the development of computational models of device-related thrombosis has focused on platelet activity. While those models have been successful in predicting thrombus formation in medical devices operating at high shear rates (> 5000 s−1), they cannot be directly applied to low-shear devices, such as blood oxygenators and catheters, where emerging information suggest that fibrin formation is the predominant mechanism of clotting and platelet activity plays a secondary role. In the current work, we augment an existing platelet-based model of thrombosis with a partial model of the coagulation cascade that includes contact activation of factor XII and fibrin production. To calibrate the model, we simulate a backward-facing-step flow channel that has been extensively characterized in-vitro. Next, we perform blood perfusion experiments through a microfluidic chamber mimicking a hollow fiber membrane oxygenator and validate the model against these observations. The simulation results closely match the time evolution of the thrombus height and length in the backward-facing-step experiment. Application of the model to the microfluidic hollow fiber bundle chamber capture both gross features such as the increasing clotting trend towards the outlet of the chamber, as well as finer local features such as the structure of fibrin around individual hollow fibers. Our results are in line with recent findings that suggest fibrin production, through contact activation of factor XII, drives the thrombus formation in medical devices operating at low shear rates with large surface area to volume ratios.
- Open Access
A fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas
Over the past decade, much of the development of computational models of device-related thrombosis has focused on platelet activity. While those models have been successful in predicting thrombus formation in medical devices operating at high shear rates ( > 5000 s −1 ), they cannot be directly applied to low-shear devices, such as blood oxygenators and catheters, where emerging information suggest that fibrin formation is the predominant mechanism of clotting and platelet activity plays a secondary role. In the current work, we augment an existing platelet-based model of thrombosis with a partial model of the coagulation cascade that includes contact activation of factor XII and fibrin production. To calibrate the model, we simulate a backward-facing-step flow channel that has been extensively characterized in-vitro. Next, we perform blood perfusion experiments through a microfluidic chamber mimicking a hollow fiber membrane oxygenator and validate the model against these observations. The simulation results closely match the time evolution of the thrombus height and length in the backward-facing-step experiment. Application of the model to the microfluidic hollow fiber bundle chamber capture both gross features such as the increasing clotting trend towards the outlet of the chamber, as well as finer local features such as the structure of fibrin around individual hollow fibers. Our results are in line with recent findings that suggest fibrin production, through contact activation of factor XII, drives the thrombus formation in medical devices operating at low shear rates with large surface area to volume ratios. Author summary: Patients treated with blood-contacting medical devices suffer from clotting complications. Over the past decades, a great effort has been made to develop computational tools to predict and prevent clot formation in these devices. However, most models have focused on platelet activity and neglected other important parts of the problem such as the coagulation cascade reactions that lead to fibrin formation. In the current work, we incorporate this missing element into a well-established and validated model for platelet activity. We then use this novel approach to predict thrombus formation in two experimental configurations. Our results confirm that to accurately predict the clotting process in devices where surface area to volume ratios are large and flow velocity and shear stresses remain low, coagulation reactions and subsequent fibrin formation must be considered. This new model could have great implications for the design and optimization of medical devices such as blood oxygenators. In the long term, the model could evolve into a functional tool to inform anticoagulation therapies for these patients.
Open AccessA fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas
Over the past decade, much of the development of computational models of device-related thrombosis has focused on platelet activity. While those models have been successful in predicting thrombus formation in medical devices operating at high shear rates ( > 5000 s −1 ), they cannot be directly applied to low-shear devices, such as blood oxygenators and catheters, where emerging information suggest that fibrin formation is the predominant mechanism of clotting and platelet activity plays a secondary role. In the current work, we augment an existing platelet-based model of thrombosis with a partial model of the coagulation cascade that includes contact activation of factor XII and fibrin production. To calibrate the model, we simulate a backward-facing-step flow channel that has been extensively characterized in-vitro. Next, we perform blood perfusion experiments through a microfluidic chamber mimicking a hollow fiber membrane oxygenator and validate the model against these observations. The simulation results closely match the time evolution of the thrombus height and length in the backward-facing-step experiment. Application of the model to the microfluidic hollow fiber bundle chamber capture both gross features such as the increasing clotting trend towards the outlet of the chamber, as well as finer local features such as the structure of fibrin around individual hollow fibers. Our results are in line with recent findings that suggest fibrin production, through contact activation of factor XII, drives the thrombus formation in medical devices operating at low shear rates with large surface area to volume ratios. Author summary: Patients treated with blood-contacting medical devices suffer from clotting complications. Over the past decades, a great effort has been made to develop computational tools to predict and prevent clot formation in these devices. However, most models have focused on platelet activity and neglected other important parts of the problem such as the coagulation cascade reactions that lead to fibrin formation. In the current work, we incorporate this missing element into a well-established and validated model for platelet activity. We then use this novel approach to predict thrombus formation in two experimental configurations. Our results confirm that to accurately predict the clotting process in devices where surface area to volume ratios are large and flow velocity and shear stresses remain low, coagulation reactions and subsequent fibrin formation must be considered. This new model could have great implications for the design and optimization of medical devices such as blood oxygenators. In the long term, the model could evolve into a functional tool to inform anticoagulation therapies for these patients.
- 5 April 2022
- Published by Wiley in International Journal for Numerical Methods in Biomedical Engineering
- Vol. 38 (5) , e3595
Uncertainty quantification of a thrombosis model considering the clotting assay PFA‐100®
Mathematical models of thrombosis are currently used to study clinical scenarios of pathological thrombus formation. As these models become more complex to predict thrombus formation dynamics high computational cost must be alleviated and inherent uncertainties must be assessed. Evaluating model uncertainties allows to increase the confidence in model predictions and identify avenues of improvement for both thrombosis modeling and anti‐platelet therapies. In this work, an uncertainty quantification analysis of a multi‐constituent thrombosis model is performed considering a common assay for platelet function (PFA‐100®). The analysis is facilitated thanks to time‐evolving polynomial chaos expansions used as a parametric surrogate for the full thrombosis model considering two quantities of interest; namely, thrombus volume and occlusion percentage. The surrogate is thoroughly validated and provides a straightforward access to a global sensitivity analysis via computation of Sobol' coefficients. Six out of 15 parameters linked to thrombus consitution, vWF activity, and platelet adhesion dynamics were found to be most influential in the simulation variability considering only individual effects; while parameter interactions are highlighted when considering the total Sobol' indices. The influential parameters are related to thrombus constitution, vWF activity, and platelet to platelet adhesion dynamics. The surrogate model allowed to predict realistic PFA‐100® closure times of 300,000 virtual cases that followed the trends observed in clinical data. The current methodology could be used including common anti‐platelet therapies to identify scenarios that preserve the hematological balance.
- 5 April 2022
- Published by Wiley in International Journal for Numerical Methods in Biomedical Engineering
- Vol. 38 (5) , e3595
Uncertainty quantification of a thrombosis model considering the clotting assay PFA‐100®
Mathematical models of thrombosis are currently used to study clinical scenarios of pathological thrombus formation. As these models become more complex to predict thrombus formation dynamics high computational cost must be alleviated and inherent uncertainties must be assessed. Evaluating model uncertainties allows to increase the confidence in model predictions and identify avenues of improvement for both thrombosis modeling and anti‐platelet therapies. In this work, an uncertainty quantification analysis of a multi‐constituent thrombosis model is performed considering a common assay for platelet function (PFA‐100®). The analysis is facilitated thanks to time‐evolving polynomial chaos expansions used as a parametric surrogate for the full thrombosis model considering two quantities of interest; namely, thrombus volume and occlusion percentage. The surrogate is thoroughly validated and provides a straightforward access to a global sensitivity analysis via computation of Sobol' coefficients. Six out of 15 parameters linked to thrombus consitution, vWF activity, and platelet adhesion dynamics were found to be most influential in the simulation variability considering only individual effects; while parameter interactions are highlighted when considering the total Sobol' indices. The influential parameters are related to thrombus constitution, vWF activity, and platelet to platelet adhesion dynamics. The surrogate model allowed to predict realistic PFA‐100® closure times of 300,000 virtual cases that followed the trends observed in clinical data. The current methodology could be used including common anti‐platelet therapies to identify scenarios that preserve the hematological balance.
- Open Access
- 16 August 2021
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 49 (9) , 2646-2658
A Continuum Model for the Unfolding of von Willebrand Factor
Von Willebrand Factor is a mechano-sensitive protein circulating in blood that mediates platelet adhesion to subendothelial collagen and platelet aggregation at high shear rates. Its hemostatic function and thrombogenic effect, as well as susceptibility to enzymatic cleavage, are regulated by a conformational change from a collapsed globular state to a stretched state. Therefore, it is essential to account for the conformation of the vWF multimers when modeling vWF-mediated thrombosis or vWF degradation. We introduce a continuum model of vWF unfolding that is developed within the framework of our multi-constituent model of platelet-mediated thrombosis. The model considers two interconvertible vWF species corresponding to the collapsed and stretched conformational states. vWF unfolding takes place via two regimes: tumbling in simple shear and strong unfolding in flows with dominant extensional component. These two regimes were demonstrated in a Couette flow between parallel plates and an extensional flow in a cross-slot geometry. The vWF unfolding model was then verified in several microfluidic systems designed for inducing high-shear vWF-mediated thrombosis and screening for von Willebrand Disease. The model predicted high concentration of stretched vWF in key regions where occlusive thrombosis was observed experimentally. Strong unfolding caused by the extensional flow was limited to the center axis or middle plane of the channels, whereas vWF unfolding near the channel walls relied upon the shear tumbling mechanism. The continuum model of vWF unfolding presented in this work can be employed in numerical simulations of vWF-mediated thrombosis or vWF degradation in complex geometries. However, extending the model to 3-D arbitrary flows and turbulent flows will pose considerable challenges.
- 16 August 2021
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 49 (9) , 2646-2658
Open AccessA Continuum Model for the Unfolding of von Willebrand Factor
Von Willebrand Factor is a mechano-sensitive protein circulating in blood that mediates platelet adhesion to subendothelial collagen and platelet aggregation at high shear rates. Its hemostatic function and thrombogenic effect, as well as susceptibility to enzymatic cleavage, are regulated by a conformational change from a collapsed globular state to a stretched state. Therefore, it is essential to account for the conformation of the vWF multimers when modeling vWF-mediated thrombosis or vWF degradation. We introduce a continuum model of vWF unfolding that is developed within the framework of our multi-constituent model of platelet-mediated thrombosis. The model considers two interconvertible vWF species corresponding to the collapsed and stretched conformational states. vWF unfolding takes place via two regimes: tumbling in simple shear and strong unfolding in flows with dominant extensional component. These two regimes were demonstrated in a Couette flow between parallel plates and an extensional flow in a cross-slot geometry. The vWF unfolding model was then verified in several microfluidic systems designed for inducing high-shear vWF-mediated thrombosis and screening for von Willebrand Disease. The model predicted high concentration of stretched vWF in key regions where occlusive thrombosis was observed experimentally. Strong unfolding caused by the extensional flow was limited to the center axis or middle plane of the channels, whereas vWF unfolding near the channel walls relied upon the shear tumbling mechanism. The continuum model of vWF unfolding presented in this work can be employed in numerical simulations of vWF-mediated thrombosis or vWF degradation in complex geometries. However, extending the model to 3-D arbitrary flows and turbulent flows will pose considerable challenges.